DNAA - DNAA STOCK NEWS

Akili Interactive, a digital medicine company, will present at Cowen’s 42nd Annual Health Care Conference on March 8, 2022, at 12:50 p.m. E.T. The presentation comes as Akili continues its innovative work in developing cognitive treatments via engaging technologies. Earlier this year, on January 26, 2022, Akili announced plans to become publicly traded through a merger with Social Capital Suvretta Holdings Corp. I (DNAA). The merger is expected to complete in mid-2022, with Akili subsequently trading on NASDAQ under the ticker AKLI.

Akili Interactive, a leader in digital medicine, announced that CFO Santosh Shanbhag and VP of Marketing Blake Schiller will speak at the fifth annual DTx West event on February 23, 2022. Shanbhag will discuss DTx mergers and acquisitions at 10:55 a.m. PT, while Schiller will address collaborations between DTx and pharmaceutical companies at 2:40 p.m. PT. Akili is set to go public through a merger with Social Capital Suvretta Holdings Corp. I (Nasdaq: DNAA), expected to close by mid-2022. This marks a significant step in advancing cognitive treatments validated by clinical trials.

PureTech Health announced significant findings from a study on AKL-T01 (EndeavorRx) for children with ADHD. The research demonstrated enhanced brain activity related to attention, as evidenced by increased midline frontal theta (MFT) activity in EEG readings. This activity correlated with improved behavioral measures, as parents reported a decrease in inattention symptoms. The study, published in PLOS ONE, reinforces EndeavorRx's efficacy in targeting cognitive functions, paving the way for ongoing clinical development and commercialization.

Akili Interactive Labs has published data demonstrating that its digital therapeutic, AKL-T01 (EndeavorRx), enhances brain activity linked to attention in children aged 8-12 with ADHD. Conducted by notable researchers, the unblinded study showed increased midline frontal theta (MFT) activity via EEG, which correlated with improvements in attentional control. Results were published in PLOS ONE. The treatment is FDA-cleared for children with ADHD, and Akili is expected to launch EndeavorRx commercially in late 2022 following a merger with Social Capital Suvretta Holdings Corp. I (Nasdaq: DNAA).

PureTech Health (Nasdaq: PRTC) announces that its Founded Entity, Akili Interactive, has filed a Form S-4 registration with the SEC concerning its proposed business combination with Social Capital Suvretta Holdings Corp. I (Nasdaq: DNAA). This filing includes a preliminary proxy statement/prospectus with critical details about Akili. The merger is anticipated to conclude by mid-2022, leading to Akili being listed on Nasdaq under the new ticker symbol “AKLI.” The registration statement is available for review on the SEC's website.

Akili Interactive has announced that Social Capital Suvretta Holdings Corp. I (DNAA) filed a registration statement with the SEC regarding its proposed business combination with Akili. This follows their earlier announcement and aims for a mid-2022 closing, resulting in the combined entity being listed on Nasdaq under the ticker symbol "AKLI." The registration statement contains crucial information about both companies and the transaction, although it remains subject to change and has not yet become effective.

Brodsky & Smith has initiated investigations regarding possible fiduciary duty breaches by the Boards of several SPACs, including Sports Ventures Acquisition Corp. (AKIC). The investigation focuses on whether the Boards conducted fair processes during their mergers, particularly concerning shareholder dilution. In the case of AKIC, the company plans to merge with DNEG, a visual effects and animation firm, retaining 14.9% ownership for Sports Ventures shareholders. Concerns are raised about potential financial implications and governance standards.